MDalert.com is designed to help physicians in all specialties succeed in this new world of performance-driven healthcare.
September 10, 2021

Manufacturer Withdraws Atezolizumab from FDA Accelerated Approval for Triple-negative Breast Cancer

By Andrew John, Pharm /alert Contributor
Genentech has voluntarily withdrawn the accelerated approval of atezolizumab (Tecentriq) combined with albumin-bound paclitaxel as a first-line treatment for patients with locally advanced or metastatic PD-L1-positive, triple-negative breast cancer...
Manufacturer Withdraws Atezolizumab from FDA Accelerated Approval for Triple-negative Breast Cancer
September 8, 2021

FDA Grants Clearance to Novel Car T Therapy KITE-363 for Treatment of Patients With LBCL

By Cameron Kelsall, MD /alert Contributor
An Investigational New Drug application for KITE-363, a chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD20, has been cleared by the US Food and Drug Administration (FDA)...
FDA Grants Clearance to Novel Car T Therapy KITE-363 for Treatment of Patients With LBCL
September 7, 2021

‘Results Do Not Support’ Avelumab as Frontline Ovarian Cancer Therapy

By Andrew John, MD /alert Contributor
Avelumab did not appear to be a suitable frontline treatment for patients with advanced epithelial ovarian cancer...
‘Results Do Not Support’ Avelumab as Frontline Ovarian Cancer Therapy
September 6, 2021

Hypofractionated Image-Guided Radiotherapy Offers No Benefit Over Conventionally Fractionated Radiotherapy

By Michael Vlessides, MD /alert Contributor

For patients with stage II/III non small-cell lung cancer who are ineligible for concurrent chemoradiotherapy, the use of hypofractionated image-guided radiotherapy offers no benefit over conventionally fractionated radiotherapy...
Hypofractionated Image-Guided Radiotherapy Offers No Benefit Over Conventionally Fractionated Radiotherapy
September 3, 2021

BTK, mTOR Inhibitor Combination Lacks Efficacy in Patients With Relapsed, Refractory DLBCL

By Cameron Kelsall, MD /alert Contributor
The addition of vistusertib to acalabrutinib, a covalent Bruton’s tyrosine kinase inhibitor approved for the treatment of patients with B-cell lymphomas, did not increase the clinical activity when the two agents were administered as a combined treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)...
BTK, mTOR Inhibitor Combination Lacks Efficacy in Patients With Relapsed, Refractory DLBCL
View More
Loading...

Trending News

In cooperation with Reuters News and Reuters Health, we are proud to provide you with our continuously updated news feed. We select news that applies to physicians in all the major clinical specialties, as well as on finance, science, technology, and other areas.

Reuters Health Medical News

UPDATE 5-U.S. FDA advisers recommend COVID-19 boosters for older adults after rejecting broad approval

(Recasts with new vote) By Manojna Maddipatla and Michael Erman (Reuters) - A panel of expert outside advisers to the U.S. Food and Drug Administration voted on Friday to recommend COVID-19 vaccine Read More »

Monitoring PA pressure likely curbs heart-failure hospitalization in obese

By Marilynn Larkin NEW YORK (Reuters Health) - Pulmonary artery (PA) pressure monitoring reduced hospitalizations of obese patients with heart failure, regardless of ejection fraction (EF), in a Read More »

Enfortumab vedotin may trigger rare, severe skin reactions

By Marilynn Larkin NEW YORK (Reuters Health) - Post-marketing surveillance of the urothelial cancer drug enfortumab vedotin (EV) uncovered cases of Stevens-Johnson Syndrome (SJS) and toxic epidermal Read More »

Genetic testing in early AF may reveal more serious congenital problems

By Marilynn Larkin NEW YORK (Reuters Health) - Genetic testing in patients with early-onset atrial fibrillation (AF) identified a more serious disease-associated variant in 10% of cases, researchers Read More »

Circadian system implicated in asthma worsening at night

By Marilynn Larkin NEW YORK (Reuters Health) - The circadian system plays an important role in nocturnal worsening of asthma, independent of sleep and other daily behavioral or environmental cycles, Read More »

EXPLAINER-The case for, and against, COVID-19 vaccine boosters

By Reuters Staff NEW YORK (Reuters) - The U.S. government aims to begin offering COVID-19 vaccine booster shots widely next week to Americans age 16 and up. A panel of outside advisers to the Food and Read More »

U.S. FDA vaccine advisers vote in favor of COVID-19 booster shot for those 65 and older

By Reuters Staff (Reuters) - A panel of expert outside advisers to the U.S. Food and Drug Administration voted on Friday to recommend COVID-19 vaccine booster shots for Americans 65 and older and Read More »

Biden adds measles to list of diseases that could require quarantine

By Reuters Staff WASHINGTON (Reuters) - President Joe Biden on Friday signed an executive order adding measles to a list of communicable diseases that could require quarantine after several Afghan Read More »

See all news »

Clinical Trials

Use our ClinicalTrials.gov feed to find trials in which your patients could enroll. In some cases, experimental drugs are a patient’s only hope. This section will regularly report on trials in the most common disease states, as they are getting underway.


© 2021 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information